Exagen Inc. (XGN)
- Previous Close
1.3700 - Open
1.3700 - Bid --
- Ask --
- Day's Range
1.3700 - 1.4098 - 52 Week Range
1.3000 - 3.9230 - Volume
2,617 - Avg. Volume
38,346 - Market Cap (intraday)
23.785M - Beta (5Y Monthly) 1.19
- PE Ratio (TTM)
-- - EPS (TTM)
-1.3400 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.50
Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
www.exagen.com174
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: XGN
Performance Overview: XGN
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: XGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: XGN
Valuation Measures
Market Cap
23.79M
Enterprise Value
11.01M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.46
Price/Book (mrq)
1.05
Enterprise Value/Revenue
0.21
Enterprise Value/EBITDA
-0.58
Financial Highlights
Profitability and Income Statement
Profit Margin
-45.08%
Return on Assets (ttm)
-19.94%
Return on Equity (ttm)
-72.72%
Revenue (ttm)
52.55M
Net Income Avi to Common (ttm)
-23.69M
Diluted EPS (ttm)
-1.3400
Balance Sheet and Cash Flow
Total Cash (mrq)
36.49M
Total Debt/Equity (mrq)
106.10%
Levered Free Cash Flow (ttm)
-9.27M